Opendata, web and dolomites

iSTantibody SIGNED

An innovative & seamless approach for the mass spectrometry analysis of monoclonal antibodies

Total Cost €


EC-Contrib. €






 iSTantibody project word cloud

Explore the words cloud of the iSTantibody project. It provides you a very rough idea of what is the project "iSTantibody" about.

95    staff    final    diseases    handling    poorly    eliminating    effectiveness    revolutionise    sensitivity    biopharma    free    worldwide    automated    pharma    2022    consists    safety    therapeutic    consumables    performed    volume    manifold    ahead    customers    ms    simplify    plugged    notably    gt    istantibody    tight    scientists    multiplexed    ist    context    patented    patients    date    cagr    billion    12    scientific    portfolio    shorten    kit    reproducible    time    drawing    tackles    preparations    tools    antibodies    revenues    monoclonal    complicated    mabs    benefits    preparation    company    broad    creation    young    skilled    million    proprietary    employability    market    opening    consequent    possibility    innovative    purification    protocols    consuming    mass    liquid    perspectives    streamlined    guarantee    remarkable    purity    seize    proteomics    advantages    companies    spectrometry    13    jobs    translates    characterised    benefit    german    preomics    15    pitfalls    seeking    contaminants    platforms    significantly    easily    2026    technique    panel    forecasted    standard    innovation   

Project "iSTantibody" data sheet

The following table provides information about the project.


Organization address
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PREOMICS GMBH DE (PLANEGG MARTINSRIED) coordinator 50˙000.00


 Project objective

Therapeutic monoclonal antibodies (mAbs) are innovative therapeutic tools that are currently drawing the attention of biopharma companies for their effectiveness against a broad panel of diseases. To guarantee safety for patients, tight control over the purity of mAbs preparations is crucial. The presence of contaminants in mAbs preparations can be assessed using mass spectrometry (MS), a technique characterised by remarkable sensitivity, but which requires a time-consuming, complicated and poorly reproducible sample preparation. Notably, at today’s date, this process cannot be automated or multiplexed: it has to be performed by highly skilled scientific staff, and - importantly - it cannot be easily “plugged in” the streamlined production approaches of pharma companies. PreOmics is a young German company seeking to revolutionise the MS proteomics market with its proprietary technology portfolio. Through the iSTantibody project, PreOmics translates its patented iST technology in the context of mAbs MS analysis and tackles the current pitfalls of mAbs sample preparation. Its final goal consists of a kit to simplify and shorten MS sample preparation by > 95% compared to standard protocols, eliminating the need for skilled scientists and allowing MS sample purification on automated liquid handling platforms. The advantages for potential customers are manifold – notably, significantly reduced costs, and the consequent possibility to free resources for mAbs development. The target sector of iSTantibody is the ever-growing market for MS sample preparation consumables, which is forecasted to reach a volume of € 1.3 billion worldwide in 2022, at a CAGR of 12%. The benefit of the iSTantibody project will produce remarkable benefits for PreOmics, both in terms of increased revenues ( € 15.3 million in 2026), employability (creation of 13 jobs) and innovation potential, opening new market perspectives and allowing PreOmics to seize more opportunities in the years ahead.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ISTANTIBODY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ISTANTIBODY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More